Scientists are exploring whether aging can be slowed or even reversed, but experts caution that promising laboratory results do not yet guarantee meaningful benefits for people.

The growing longevity industry is attracting billions of dollars in investment and building on decades of research into the biology of aging. Its central question is ambitious: Can scientists safely slow aging, prevent age-related diseases, or restore health in older adults?

Some academics and pharmaceutical companies are taking a cautious approach. They argue that many proposed treatments have not yet been proven in large, well-designed human trials, or shown to be commercially viable.

Others believe the field is moving too quickly to dismiss. Researchers, entrepreneurs, patients, and advocates point to encouraging findings in laboratory animals and early human studies. They argue that progress requires testing promising ideas rather than waiting for absolute certainty.

Not all longevity treatments have the same evidence

A recent review of drugs that target aging-related biological pathways highlights both the promise and the uncertainty surrounding geroscience, the study of how aging contributes to disease.

However, experts warn that the broad term “longevity industry” can hide major differences between treatments.

For example, NAD+ boosters and senolytic drugs are sometimes discussed together, even though the evidence behind them is very different. NAD+ approaches have produced inconsistent animal findings, relatively small effects, and a history of disappointing human trials in several medical areas.

Senolytics, by contrast, are designed to remove senescent “zombie” cells, damaged cells that stop dividing but can release harmful signals. These treatments have produced more consistent and substantial results in animal studies, including improvements in some age-related conditions.

Human evidence, however, remains limited and mixed because only a small number of early trials have been completed.

Existing drugs are being reexamined

Researchers are also studying whether established medicines could help protect against the effects of aging.

• Metformin and rapamycin have some of the strongest preclinical and early translational evidence, although their ability to broadly extend healthy human lifespan has not been demonstrated.
• Statins, SGLT2 inhibitors, and GLP-1 medicines already provide important benefits for specific cardiovascular and metabolic diseases. Whether they directly slow biological aging remains unknown.
• Menopausal hormone therapy may offer certain health benefits, but its broader effects on aging and healthspan are still being studied.
• Taurine, NAD+ precursors, senolytics, and epigenetic reprogramming are at different stages of development, ranging from promising laboratory work to early human research.

The key distinction is between changing an aging-related biomarker and producing a meaningful improvement in health. A treatment may alter molecular measurements without helping people live healthier, longer lives.

Major questions remain unanswered

The field still lacks universally accepted measures of biological aging and clear clinical standards for proving that a treatment extends healthspan. Researchers also need better answers about:

• Which people are most likely to benefit
• The best age to begin treatment
• How long treatments should continue
• Whether benefits apply broadly or only to specific diseases
• What risks may emerge after years of use

The next phase of geroscience will depend on large, carefully designed clinical trials. These studies will need to combine biological-age measurements with outcomes that matter to patients, such as preventing disease, maintaining independence, and improving quality of life.

Geroscience remains a promising but unfinished scientific endeavor. Its future will be determined not by laboratory excitement alone, but by whether these interventions can deliver safe, measurable, and lasting benefits for people.